# A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer

> **NCT06685796** · PHASE2 · RECRUITING · sponsor: **BeBetter Med Inc** · enrollment: 120 (estimated)

## Conditions studied

- Advanced Triple-Negative Breast Cancer

## Interventions

- **DRUG:** BEBT-209 capsules
- **DRUG:** Carboplatin injection
- **DRUG:** Gemcitabine hydrochloride for injection

## Key facts

- **NCT ID:** NCT06685796
- **Lead sponsor:** BeBetter Med Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-12
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06685796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06685796, "A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06685796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*